CLAIM #2688 · AbbVie Inc (ABBV) · 2025Q3 earnings call · Oct 31, 2025 · due Jan 31, 2026
“the Phase Ib program late this year, maybe into January when we get everything started.”
Roopal Thakkar · EVP, R&D, Chief Scientific Officer
PENDING
graded after results covering Jan 31, 2026 are reported
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2025Q3 earnings call.